Henry Wheeler

Henry joined Innate Pharma as Vice President, Investor Relations in June 2021 and was appointed to the executive committee in January 2023. Henry has over 15 years’ experience across the pharmaceutical and financial industries. Henry joined from AstraZeneca, where he led investor relations for the company’s oncology portfolio, having previously served within AstraZeneca’s Oncology Business Unit. Prior to this, Henry worked in various healthcare financial roles including at Third Bridge and Morgan Stanley in London.

Henry graduated with a MSc in Drug Discovery Skills and a BSc with honours in Pharmacology, both from King‘s College, London.